Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
EBIT MarginEBITDA MarginEBT MarginFCF MarginInterest Coverage RatioNet MarginOperating MarginReturn on SalesTimes Interest Earned

Alx Oncology Holdings (ALXO) Net Margin (2019 - 2023)

Alx Oncology Holdings' Net Margin history spans 4 years, with the latest figure at 21943.61% for Q4 2023.

  • For Q4 2023, Net Margin fell 3520898.0% year-over-year to 21943.61%; the TTM value through Dec 2023 reached 1577.32%, down 5026974.0%, while the annual FY2025 figure was 31.02%, 776828.0% down from the prior year.
  • Net Margin for Q4 2023 was 21943.61% at Alx Oncology Holdings, down from 13040.66% in the prior quarter.
  • Across five years, Net Margin topped out at 1765650.0% in Q3 2022 and bottomed at 21943.61% in Q4 2023.
  • The 4-year median for Net Margin is 8546.83% (2023), against an average of 353792.79%.
  • The largest YoY upside for Net Margin was -3520898bps in 2023 against a maximum downside of -175260934bps in 2023.
  • A 4-year view of Net Margin shows it stood at 728.36% in 2019, then plummeted by -264bps to 2651.23% in 2020, then skyrocketed by 600bps to 13265.37% in 2022, then plummeted by -265bps to 21943.61% in 2023.
  • Per Business Quant, the three most recent readings for ALXO's Net Margin are 21943.61% (Q4 2023), 13040.66% (Q3 2023), and 9269.62% (Q2 2023).